Ted Karkus : So it’s interesting, your commentary is spot on. And you just sort of proved my point that this business is in — its infancy, we’re just getting started here, and the demand is about to explode. And we quickly weren’t going to spread around the country. We were the low cost provider. What a great business to be in. But while you were speaking, it reminded me this critically important. We were about to get into genetic counseling. And so the beauty of that is people that don’t really know anything about whole genome sequencing, get their reports. It’s like, okay, what’s the next step? What do you do with these reports, they will have a genetic counselor review their reports with them. So we’re going to build a business model around that, and a partnership around that, that’s only going to make our offerings even more attractive.
That’s primarily on the consumer side, but also understand when I start talking about, these physician networks, and telemedicine platforms, our genetic counseling could also play an important role there as well. I mean, after all, physicians, typically are not experts in genetics. And so genetic counselors could play a nice role, really complementing the physicians. So we’re going to be developing that business. Well, I’m really excited about that. When you say a year from now, what am I going to be saying about Nebula? Well, that is honestly, I could be saying, boy it wasn’t a great business that we acquired for so little and sold for so much. All right. That literally could be the conversation we begin, we could have a year from now. Another conversation we could be having is, well, I can’t believe how significant the revenues are, where do we go from here?
And we’ll only be up because at that point, that’s when the big labs are going to say, wow, now we really have to get into this business. How do we get into it? And the largest labs in the country, I think, will be knocking on our door saying we want to buy your business. And as far as revenues are concerned, I think they’re going to be dramatic. I don’t want to put a number on it makes no sense. We’re in the infancy of building this business, we’re at the starting point, I’m telling you, it’s like when we built out the COVID business three years ago, I didn’t know we’re going to do $100 million a year in revenue. I had no idea, we’d be happy with $10 million a year in revenue, and we did $100 million. Well, it’s the same dynamics with our whole genome sequencing business.
So I have no idea. I truly don’t. What I’m doing is I’m building the capacity, the infrastructure, the efficiency, the pricing, putting all that in place, we have a great team in place to execute. We have a team that’s executed on the COVID testing now they’re going to execute on the Nebula Genomics business. We have great people in place took three years to get the right people in place. And now we’re going to do same thing we did in COVID, and we’re going to do with Nebula Genomics. So it’s not like we’re new to this business. But whereas experience in genomic testing at this point does anybody in the country. So not only do we have the best equipment and the lowest pricing, but there wasn’t anybody that’s more of an expert that we’re in the lab and actually doing the whole genome sequencing.
In fact, we’re at the forefront in the U.S. — in the State of New York, which is the most highly regulated the strictest. We’re basically setting we’re setting precedents with the State of New York, that everybody else is going to follow. That’s how big this is and how serious we are about it. I just can’t believe that I’m the person sitting here in our microcap company talking. All right, I hope that answers your question. I’m certainly not giving you specifics, given those dynamics, what our revenues are going to be 12 months from, I don’t. It could be, I believe it’s going to be a hell of a lot greater than what it is right now.
Dennis Waldman : Thank you, Ted.
Ted Karkus : Let me, we’re almost out of time, if we can get to the next question. Hey, Dennis, always appreciate your support. That was a great question and great commentary. Thank you very much. Nick, back to you.
Operator: Thank you. Next question will be from Fred [Indiscernible] retail investor. Please go ahead.
Unidentified Analyst: Hi, Ted. How you doing? Ted, you’ve commented numerous times about the profits of Pharmaloz Biopharma and Nebula. But the separate work is worth greater than the current value of ProPhase. Now you say you’re not going to be doing — going to an equity raise at these prices? Would you consider doing an IPO or a spinoff, or one or all these divisions to raise their value?
Ted Karkus : Yeah, so that’s a great question. I don’t know the exact SEC rules. But in general SEC frowns upon talking about IPOs and things of that nature ahead of when you file. And so, I can’t comment other than to say, you hit the nail on the head that we will have, potentially all of these opportunities and options at our fingertips. And you can bet give my Wallstreet background and given our relationships with some great investment banks. And as I said, I’ve worked daily with big equity firms more than three years now. And they are experts in micro caps development stage, biotech and life science companies. So we’re in great hands we have a great working relationship. And I’m sure, based on everything that I described, there are going to be lots of opportunities next year.
